Online citations, reference lists, and bibliographies.
← Back to Search

A Novel Nanoparticles Impregnated Ocular Insert For Enhanced Bioavailability To Posterior Segment Of Eye: In Vitro, In Vivo And Stability Studies.

Lalaji V Rathod, R. Kapadia, K. Sawant
Published 2017 · Materials Science, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The present investigation was carried out to demonstrate with the help of in vitro and in vivo studies that nanoparticles impregnated ocular inserts effectively delivers significant concentration of drug to the posterior segment of eye after topical administration for treatment of glaucoma. Drug loaded Nanoparticles and their ocular insert have been reported to reduce side effects of orally administered Acetazolamide. Eudragit NPs were prepared by the solvent diffusion nanoprecipitation technique. The prepared NPs were evaluated for various parameters such as particle size, zeta potential, % entrapment efficiency, % drug loading, DSC, FTIR, TEM and stability studies. Ocular inserts of NPs were prepared by solvent casting method. The prepared ocular inserts were evaluated for thickness, content uniformity, folding endurance, disintegration time, morphology and stability study. The NPs and ocular inserts were evaluated for in-vitro drug diffusion study, ex-vivo trans-corneal permeability study, in-vivo ocular tolerability and intra ocular pressure (IOP) reduction study. The optimized batch was stable for a period of 3months in lyophilized form. The optimized formulations had size range of 367nm±8nm, zeta potential around +7mV±1.3mV and 51.61%±3.84% entrapment efficiency with 19%±1.40% drug loading. The ex-vivo trans-corneal study showed higher cumulative corneal permeation, flux across corneal tissue (2.460±0.028μg/ml) and apparent corneal permeability (3.926×10-6cm2/s & 3.863×10-6cm2/s) from drug loaded Eudragit NPs and Ocular inserts as compared to drug solution (0.671±0.020μg/ml & 3.166×10-6cm2/s). In-vivo study showed the Eudragit NPs and ocular insert produced significant (P<0.001) lowering in intra ocular pressure compared with the solution of free drug after 3h of topical ocular administration. Plain Eudragit NPs caused no inflammation and/or discomfort in rabbit eyes and neither affected the intra ocular pressure establishing their safety and non irritancy.
This paper references
10.3797/scipharm.1204-16
Preparation and In Vitro/Ex Vivo Evaluation of Moxifloxacin-Loaded PLGA Nanosuspensions for Ophthalmic Application
Meetali Mudgil (2013)
10.3109/02652048.2012.665088
Eudragit RL100 based microspheres for ocular administration of azelastine hydrochloride
U. Shinde (2012)
10.1016/j.jconrel.2009.04.035
An efficient ternary complex of acetazolamide with HP-ss-CD and TEA for topical ocular administration.
S. Palma (2009)
10.1002/JPS.10227
Ocular tolerability of Eudragit RS100 and RL100 nanosuspensions as carriers for ophthalmic controlled drug delivery.
R. Pignatello (2002)
Design of Eudragit RL 100 nanoparticles by nanoprecepitation method for ocular drug delivery , Nanomed . : Nanotechnol .
P. K. Suresh (2010)
10.1016/S0928-0987(02)00057-X
Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.
R. Pignatello (2002)
10.1016/J.IJPHARM.2004.09.019
Oral evaluation in rabbits of cyclosporin-loaded Eudragit RS or RL nanoparticles.
N. Ubrich (2005)
Review of ocular drug delivery, Curr. Drug Deliv
Y. Sultana (2006)
10.3109/1061186X.2010.504268
Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery
H. Gupta (2011)
10.1016/0169-409X(95)00017-2
Microspheres and nanoparticles used in ocular delivery systems
A. Zimmer (1995)
10.5497/WJP.V2.I2.47
Ocular drug delivery systems: An overview.
Ashaben D. Patel (2013)
10.1159/000065608
Enhanced Ocular Anti-Inflammatory Activity of Ibuprofen Carried by an Eudragit RS100® Nanoparticle Suspension
C. Bucolo (2002)
Modelling and comparison of dissolution pro fi le , Eur
S. J. Turco N. V. Mulye (2001)
10.1016/S0306-3623(98)00196-7
The effect of topical diltiazem on ocular hypertension induced by water loading in rabbits.
J. Santafé (1999)
10.1002/JPS.2600521210
MECHANISM OF SUSTAINED-ACTION MEDICATION. THEORETICAL ANALYSIS OF RATE OF RELEASE OF SOLID DRUGS DISPERSED IN SOLID MATRICES.
T. Higuchi (1963)
10.3109/10837450903262017
Controlled release polymeric ocular delivery of acyclovir
P. Deshpande (2010)
EUDRAGIT-BASED NANOSTRUCTURES: A POTENTIAL APPROACH FOR OCULAR DRUG DELIVERY
H. Pandey (2012)
10.1080/107175401300002748
Preparation and analgesic activity of Eudragit RS100 microparticles containing diflunisal.
R. Pignatello (2001)
10.1002/ARDP.19843170314
pH‐Solubility Relationship and Partition Coefficients for some Anti‐Inflammatory Arylaliphatic Acids
A. Chiarini (1984)
10.1016/j.nano.2009.09.002
Design of Eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery.
Swarnali Das (2010)
10.1016/J.POWTEC.2011.12.046
Comparison of physicochemical characteristics and drug release of diclofenac sodium–eudragit® RS100 nanoparticles and solid dispersions
M. Barzegar-Jalali (2012)
10.1016/j.jconrel.2008.12.018
Polymeric nanoparticulate system: a potential approach for ocular drug delivery.
R. C. Nagarwal (2009)
Corneal penetration behavior of beta-blocking agents I: Physiochemical factors.
R. Schoenwald (1983)
s
J. Santafe (1999)
Factorial design, physicochemical characterisation and activity of ciprofloxacin-loaded PLGA nanoparticles for ocular use.
K. Dillen (2005)
10.1208/s12249-008-9139-4
Effect of pH and Formulation Variables on In Vitro Transcorneal Permeability of Flurbiprofen: A Technical Note
Sajeev Chandran (2008)
10.22377/AJP.V2I4.191
Development and characterization of transdermal therapeutics system of tramadol hydrochloride
Anil J Shinde (2008)
10.1177/001452469000101110
"J."
G.G. Stokes (1890)
10.1208/pt070127
Preparation and characterization of Eudragit Retard nanosuspensions for the ocular delivery of cloricromene
R. Pignatello (2008)
10.1023/B:PHAM.0000036917.75634.be
Physicochemical Parameters Associated with Nanoparticle Formation in the Salting-Out, Emulsification-Diffusion, and Nanoprecipitation Methods
S. Galindo-Rodriguez (2004)
10.3109/03639049509026658
A simple model based on first order kinetics to explain release of highly water soluble drugs from porous dicalcium phosphate dihydrate matrices
N. Mulye (1995)
10.1016/J.IJPHARM.2005.09.023
Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide.
Ahmed S. Guinedi (2005)
10.1201/9780849374555.CH11
Nanoparticles for Ocular Drug Delivery
A. Amrite (2006)
10.1007/s11095-005-4596-x
Chitosan Nanoparticles as New Ocular Drug Delivery Systems: In Vitro Stability, in Vivo Fate, and Cellular Toxicity
A. Campos (2005)
Sulfacetamide loaded Eudragit® RL100 nanosuspension with potential for ocular delivery.
B. Mandal (2010)
10.1248/YAKUSHI.127.1739
In vitro corneal permeation of diclofenac from oil drops.
M. Ahuja (2007)
10.2174/156720106776359186
Review of ocular drug delivery.
Y. Sultana (2006)
10.1002/JPS.2600721108
Corneal Penetration Behavior of β-Blocking Agents I: Physicochemical Factors
Hong-Shian Huang (1983)
10.1016/S0378-5173(00)00359-8
Formulation and evaluation of ophthalmic preparations of acetazolamide.
I. P. Kaur (2000)
Mechanism of sustained-action medication
T. Highuchi (1963)
10.1023/B:PHAM.0000026432.75781.cb
Chitosan Nanoparticles as New Ocular Drug Delivery Systems: in Vitro Stability, in Vivo Fate, and Cellular Toxicity
A. M. de Campos (2004)
10.1016/J.IJPHARM.2006.01.041
Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles.
K. Dillen (2006)
10.1111/j.2042-7158.1996.tb03911.x
Improved Ocular Bioavailability of Indomethacin by Novel Ocular Drug Carriers
P. Calvo (1996)
10.1016/S0378-5173(00)00508-1
Ketorolac entrapped in polymeric micelles: preparation, characterisation and ocular anti-inflammatory studies.
A. Gupta (2000)
Analysis of Fickian and non-Fickian drug release from polymers.
N. Peppas (1985)
10.1016/S0928-0987(01)00095-1
Modeling and comparison of dissolution profiles.
P. Costa (2001)
10.1016/S0142-9612(02)00080-7
Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application.
R. Pignatello (2002)
Novel approaches to ocular drug delivery.
J. Davis (2004)
10.1080/02652040310001637820
Effects of the permeability characteristics of different polymethacrylates on the pharmaceutical characteristics of verapamil hyhdrochloride-loaded microspheres
Muge Kilicarslan (2004)
10.1016/0378-5173(83)90064-9
Mechanisms of solute release from porous hydrophilic polymers
R. Korsmeyer (1983)
10.1248/CPB.23.3288
Rate of release of medicaments from ointment bases containing drugs in suspension.
Toshiaki Koizumi (1975)
10.1208/pt0801001
Liposomes as an ocular delivery system for acetazolamide: In vitro and in vivo studies
Rania M. Hathout (2008)
10.1002/jps.21383
PLGA nanospheres for the ocular delivery of flurbiprofen: drug release and interactions.
E. Vega (2008)
10.1016/0378-5173(89)90281-0
Nanocapsule formation by interfacial polymer deposition following solvent displacement
H. Fessi (1989)
10.18433/J3SW2T
Preparation and Physicochemical Characterization of Eudragit ® RL100 Nanosuspension with potential for Ocular Delivery of Sulfacetamide
B. Mandal (2010)
10.1080/026520499288924
Effect of formulation variables on in vitro drug release and micromeritic properties of modified release ibuprofen microspheres.
D. Perumal (1999)
10.3109/03639045.2011.555407
Influence of acetazolamide loading on the (in vitro) performances of non-phospholipid-based cationic nanosized emulsion in comparison with phospholipid-based anionic and neutral-charged nanosized emulsions
S. Tamilvanan (2011)
10.1211/002235702760089027
Characterization of Ciclosporin A loaded poly (D,L lactide‐co‐glycolide) microspheres using modulated temperature differential scanning calorimetry
N. Passerini (2002)
10.1016/S0378-5173(02)00438-6
Acetazolamide: future perspective in topical glaucoma therapeutics.
I. P. Kaur (2002)
10.1016/J.JMMM.2006.10.1170
Preparation and characterization of biodegradable magnetic carriers by single emulsion-solvent evaporation
Xianqiao Liu (2007)
10.1016/0168-3659(89)90059-X
Preparation and characterization of microspheres containing the anti-inflammatory agents, indomethacin, ibuprofen, and ketoprofen
R. Bodmeier (1989)
10.1208/pt070357
Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops
M. Rathore (2008)



This paper is referenced by
10.1016/j.colsurfb.2020.111355
Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles.
Xinyue Han (2020)
10.1080/00387010.2017.1367308
Resonance Rayleigh scattering and resonance nonlinear scattering of the palladium(II)–acetazolamide chelate with eosin Y and their analytical application
J. Li (2017)
Acetazolamide Nanosuspension: Influence of Process and Formulation Variables on Particle Size Reduction and Dissolution Enhancement
M. Donia (2018)
10.1080/02652048.2019.1662121
Cow ghee fortified ocular topical microemulsion; in vitro, ex vivo, and in vivo evaluation
Aashu Gupta (2019)
10.2147/IJN.S150366
Tailored nanostructured platforms for boosting transcorneal permeation: Box–Behnken statistical optimization, comprehensive in vitro, ex vivo and in vivo characterization
Ibrahim Elsayed (2017)
10.1016/j.msec.2018.07.065
Inner layer-embedded contact lenses for ion-triggered controlled drug delivery.
Qiang Zhu (2018)
10.1007/s12325-019-01163-6
Nanotechnology for Medical and Surgical Glaucoma Therapy—A Review
Marcelo Luís Occhiutto (2019)
10.4155/tde-2017-0018
Approaches in topical ocular drug delivery and developments in the use of contact lenses as drug-delivery devices.
P. Mehta (2017)
10.1111/bph.14024
Principles of pharmacology in the eye
S. Awwad (2017)
FORMULATION AND CHARACTERISATION OF LIPID NANOPARTICLES BEARING TAZAROTENE FOR ENHANCED TOPICAL DELIVERY IN PSORIASIS
PARMAR MAYURBHAI PRAKASHBHAI (2019)
10.2147/IJN.S254792
Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment
Song Kwon (2020)
10.1016/j.colsurfb.2020.110902
Triamcinolone acetonide loaded-cationic nano-lipoidal formulation for uveitis: Evidences of improved biopharmaceutical performance and anti-inflammatory activity.
Pradip Nirbhavane (2020)
10.1016/j.jddst.2020.101863
Preparation and characterization of anticancer niosomal withaferin–A formulation for improved delivery to cancer cells: In vitro, in vivo, and in silico evaluation
Hamid Saeed Shah (2020)
10.1007/s13346-020-00825-1
Ocular films versus film-forming liquid systems for enhanced ocular drug delivery
Hamdia G. Wafa (2020)
10.1146/annurev-vision-102016-061422
Neuroprotection in Glaucoma: Animal Models and Clinical Trials.
M. Almasieh (2017)
10.3390/pharmaceutics13010028
Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions
O. Rahić (2020)
10.1016/j.ijpharm.2020.119876
Mechanical Characteristics of Orally Disintegrating Films: Comparison of Folding Endurance and Tensile Properties.
Y. Takeuchi (2020)
10.1080/17469899.2021.1835470
Innovations and revolutions in reducing retinal ganglion cell loss in glaucoma
Mary Kelada (2020)
10.1016/j.ijbiomac.2019.08.107
Leucaena leucocephala (Lam.) galactomannan nanoparticles: Optimization and characterization for ocular delivery in glaucoma treatment.
Neeraj Mittal (2019)
10.1016/j.jconrel.2017.07.035
Novel nanosystems for the treatment of ocular inflammation: Current paradigms and future research directions
Lida Lalu (2017)
10.1016/j.jconrel.2018.06.031
Polymer‐based carriers for ophthalmic drug delivery
Julieta C. Imperiale (2018)
Semantic Scholar Logo Some data provided by SemanticScholar